Viemed Diversifies Away from Ventilation Rentals, Accepting Margin Compression for Future Scale

Record revenue and renewed ventilation growth mask a deliberate shift toward lower-margin, less capital-intensive product lines that resets the earnings quality debate.

VMD · Earnings Call · 2026-08-04

Diversification reshapes the revenue base

Viemed's second quarter was another record, but the story isn't just about growth—it's about what kind of growth. Revenue hit $78.1M, up 24% year over year, with the fastest gains coming from sleep resupply and the newly expanded maternal health business. Ventilator rental revenue, the company's historical core, grew only 8%, and now represents 47% of total revenue versus 54% a year ago. The revenue mix now tilts toward transactional sales and recurring resupply, which carry lower gross margins but also require significantly less capital.

The growing contribution from product and service revenue creates a different margin and capital profile for the company.
Todd Zehnder, Chief Executive Officer · 2026-08-04

CEO Todd Zehnder added, “We are in a growth phase, and we are investing accordingly.” — Todd Zehnder, Chief Executive Officer · 2026-08-04 That investment is visible in SG&A, which grew faster than revenue, and in a series of operational changes—from a new intake workflow to an expanded sales organization—aimed at scaling business lines.

Ventilation recovers under the new NCD

Ventilation is still the foundation, and the quarter showed it can grow under the new coverage framework. Active ventilator patients reached a record 12,635, a sequential gain of ~4.5%, and compliance improved more than 25% year over year. Management credited better referral education and internal process refinement. As Casey Hoyt said, “The second quarter combined renewed growth in ventilation with continued expansion across the broader business.” — Casey Hoyt, Chief Operating Officer · 2026-08-04 This is a theme management has repeated: on the prior call, Casey noted, “We have been leveraging that and educating our referral sources so they understand what they are up against.” — Casey Hoyt, Chief Executive Officer · 2026-05-06

Margins flex, but the model is maturing

The margin story is more nuanced. Adjusted EBITDA margin fell to 17.6% from 22.7% a year ago, but management points to the prior year's one-time equipment gains and the deliberate mix shift. Excluding those gains, EBITDA grew year over year. Gross margin was 57.7%, down 60 bps, reflecting both mix and temporary distribution costs. The company now guides to full-year revenue of $314–320M (raising the low end) and adjusted EBITDA of $64–68M (lowering the high end), while trimming net capital intensity to 8.5–10% of revenue. “We are raising the low end of our net revenue guidance and now expect full year revenue of $314 million to $320 million compared with the previous range of $312 million to $320 million.” — Todd Zehnder, Chief Executive Officer · 2026-08-04 This reflects a strategic trade-off: lower margins on product revenue but far less asset intensity, which should boost cash generation over time. Gross margin sits at 57.7% this quarter, a far cry from the 74.5% peak in 2018. The company's prior guidance for stable gross margin appears to be yielding to the new reality. On the March call, CFO Todd Zehnder said, “our goal is to try to keep gross margin as close to flat as possible.” — William Todd Zehnder, CFO · 2026-03-05

Investing for scale

Beneath the margin pressure is a deliberate push to build scalable infrastructure. The introduction of Tenor, a new intake workflow, cut order qualification time from days to under an hour and helped drive PAP setups up 16% sequentially without adding fulfillment staff. Management also brought the resupply call center in-house and is expanding maternal health fulfillment nationally. These investments are expected to improve capital efficiency and unit economics as volumes scale. Free cash flow was negative on an accounting basis, but operating cash flow was $15.9M in the quarter. Free cash flow (less SBC) was -$1M in Q2, though operating cash flow was $15.9M. The company sees these as costs of building a broader platform. The stock has pulled back about 28% from its July peak, likely reflecting the margin reset and the cost of the pivot, but the underlying growth in patients and revenue suggests the longer-term story may be intact.